200 related articles for article (PubMed ID: 37456982)
1. An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.
Snell D; Gunde T; Warmuth S; Chatterjee B; Brock M; Hess C; Johansson M; Simonin A; Spiga FM; Weinert C; Kirk N; Bassler N; Campos Carrascosa L; Flückiger N; Heiz R; Wagen S; Giezendanner N; Alberti A; Yaman Y; Mahler D; Diem D; Lichtlen P; Urech D
Oncoimmunology; 2023; 12(1):2233401. PubMed ID: 37456982
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
[TBL] [Abstract][Full Text] [Related]
3. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
4. NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors.
Grasso L; Jiang Q; Hassan R; Nicolaides NC; Kline JB
Eur J Immunol; 2023 Aug; 53(8):e2250309. PubMed ID: 37146241
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
8. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
[TBL] [Abstract][Full Text] [Related]
9. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M
Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176
[TBL] [Abstract][Full Text] [Related]
11. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.
Warmuth S; Gunde T; Snell D; Brock M; Weinert C; Simonin A; Hess C; Tietz J; Johansson M; Spiga FM; Heiz R; Flückiger N; Wagen S; Zeberer J; Diem D; Mahler D; Wickihalder B; Muntwiler S; Chatterjee B; Küttner B; Bommer B; Yaman Y; Lichtlen P; Urech D
Oncoimmunology; 2021; 10(1):2004661. PubMed ID: 35844969
[TBL] [Abstract][Full Text] [Related]
12. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
[TBL] [Abstract][Full Text] [Related]
13. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
14. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors.
Molloy ME; Austin RJ; Lemon BD; Aaron WH; Ganti V; Jones A; Jones SD; Strobel KL; Patnaik P; Sexton K; Tatalick L; Yu TZ; Baeuerle PA; Law CL; Wesche H
Clin Cancer Res; 2021 Mar; 27(5):1452-1462. PubMed ID: 33262134
[TBL] [Abstract][Full Text] [Related]
16. Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.
McCarthy D; Lofgren M; Watt A; Horton H; Kieffer-Kwon P; Ding J; Kobold S; Baeuerle PA; Hofmeister R; Gutierrez DA; Tighe R
Cancer Immunol Immunother; 2023 Dec; 72(12):4195-4207. PubMed ID: 37848682
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
[TBL] [Abstract][Full Text] [Related]
18. Generation of a Novel Mesothelin-Targeted Oncolytic
Froechlich G; Gentile C; Infante L; Caiazza C; Pagano P; Scatigna S; Cotugno G; D'Alise AM; Lahm A; Scarselli E; Nicosia A; Mallardo M; Sasso E; Zambrano N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418877
[TBL] [Abstract][Full Text] [Related]
19. A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Zitzmann-Kolbe S; Kristian A; Zopf D; Kamfenkel C; Politz O; Ellingsen C; Hilbig J; Juul MU; Fonslet J; Nielsen CH; Schatz CA; Bjerke RM; Cuthbertson AS; Mumberg D; Hagemann UB
Mol Cancer Ther; 2023 Sep; 22(9):1073-1086. PubMed ID: 37365121
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.
Ding J; Guyette S; Schrand B; Geirut J; Horton H; Guo G; Delgoffe G; Menk A; Baeuerle PA; Hofmeister R; Tighe R
Oncoimmunology; 2023; 12(1):2182058. PubMed ID: 36875551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
